Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- A library of previously synthesised PPAR agonists tested in enzyme assays
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- FAAH inhibition by a library of PPAR agonists, with a docking study of how they bind FAAH.
What the authors reported
The authors screened their PPAR agonist library for FAAH-inhibiting activity to find a lead compound with a dual PPAR/FAAH profile, and propose a binding mode from docking. The abstract names no compound and gives no potency figures. Palmitoylethanolamide is mentioned as a PPAR-acting substance, not as a test compound.
Limits of this study
An enzyme and computational study; it cannot show effect in people or animals treated in practice. No PEA was tested. The authors declare no conflict of interest.
Source
PubMed 32987725 · doi:10.3390/ijms21197026
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.